Objective: To identify risk factors associated with calcinosis in children and adolescents with juvenile dermatomyositis.
Introduction
Juvenile dermatomyositis (JDM) is a multisystemic disease of unknown etiology, which is characterized by vasculitis primarily affecting the skin and muscles. [1] [2] [3] It is part of a heterogenous group of acquired muscle diseases, the idiopathic inflammatory myopathies, whose common denominator is the presence of weak muscles with inflammatory infiltrates. Characterization of this group of pathologies is based on its pattern of muscle involvement, the presence of associated clinical manifestations, histopathological findings, response to treatment and prognosis. [4] [5] [6] This is a rare disease that predominantly affects females, at a proportion of 2:1, and which has an incidence of 3.2/ 1,000,000 children and adolescents/year in the United
States. 7 Despite its rarity, it is the fourth most frequent disease at tertiary pediatric rheumatology services, and there are no Brazilian studies of its epidemiology. 8 The initial phase of the disease is characterized by vasculitis 9 and, later, calcinosis or dystrophic calcifications may appear. 1 These are calcium deposits that appear in muscle or subcutaneous tissues. Patients with calcinosis have normal levels of calcium and phosphorous in serum, in contrast with metastatic calcifications (which are observed with hyperparathyroidism), when these metabolites are at elevated levels. 10 Calcinosis are more common in the pediatric age group, affecting from 10 to 70% of children and adolescents with JDM, compared with 30% of adults with dermatomyositis (DM). 8, 11, 12 The etiopathogenesis of calcinosis is unknown.
It is believed that calcium salt deposits occur with severe cases of the disease with persistent inflammation 13 (generalized cutaneous vasculitis, muscle weakness and sustained muscle enzyme levels in elevation) and which do not respond to corticoid therapy. 8, 10, [12] [13] [14] [15] [16] However, the majority of publications are just case reports.
There is just a single study of 35 cases that has investigated the risk factors associated with calcinosis in patients with JDM, with univariate and multivariate analysis models. 17 The rarity of research into calcinosis in JDM and the significant number of patients with this disease at our service prompted us to carry out this study.
Our objective was, therefore, to investigate risk factors (demographic data, initial and progressive clinical manifestations, laboratory tests and treatment) associated with calcinosis in children and adolescents with JDM.
Methods
This was a cross-sectional study. A total of 54 children and adolescents were studied, enrolled from those treated at the 9 and based on the presence of characteristic erythema associated with three of the four criteria listed in Table 1 .
Patients were only enrolled if all of the data described were on their medical records. These patients were followed for a minimum period of 6 months and a maximum of 16 years (mean follow-up period of 5.4 years and median of 6.7 years).
The analysis was retrospective and carried out by means of completing a protocol that covered patients' clinical, laboratory and treatment characteristics. The protocols were then divided into two groups, depending in the presence or absence of calcinosis.
Calcinosis was diagnosed based on the presence of calcium deposits that were palpable on physical examination and/or deposits visible on X-rays of soft tissues and involving the trunk, abdomen, upper and/or lower limbs. These were then classified into four subtypes: calcinosis cutis circumscripta (superficial plaques or nodules confined to the skin or subcutaneous tissue), calcinosis tumoral or universalis (large deposits that may extend to deeper tissues, including muscles), calcinosis along the muscular fascia and tendons and extensive calcium deposits all over the surface of the body. 18 All cases had normal levels of calcium and phosphorous in serum.
The two groups were compared in terms of the following characteristics: demographic data (sex, age at disease onset, time between onset of the disease and start of treatment) and The multivariate analysis employed backward stepwise logistic regression. Those independent variables that exhibited a level of statistical significance ≤ 5% were chosen for the multivariate analysis model. The level of significance was set at 5% for all tests.
Results
The principal clinical, laboratory and treatment characteristics of the 54 JDM patients are given in Table 2 .
Clinical and/or radiographic calcinosis was present in 23 (43%) patients, 15 (65%) females and eight (35%) males.
This had already appeared before JDM was diagnosed in six (26%) cases, and in one of these it was the initial manifestation of the disease. In these cases, the median time between calcinosis and diagnosis of JDM was 9 months (variation of 15 days to 2 years). The deposits appeared after diagnosis in 17 (74%) patients. Calcinosis were predominantly located in the soft tissues of upper limbs, observed in 18 (78%) patients;
followed by lower limbs in 13 (56.5%); the trunk in three (13%); scrotal and testicular region in two (8.7%) and urethral area in one (4.3%). Calcinosis circumscripta affected 15 (65%) patients, three had calcinosis universalis (13%) and there were extensive calcium deposits all over the surface of the bodies of five patients (22%).
Calcinosis was associated with persistent ulcerations in four (17%) patients, with recurrent secondary infections with Further to this there were no statistical differences between the groups with and without calcinosis in terms of: elevated muscle enzyme levels (94-100%), pulmonary involvement (14.3-30%) and cardiac involvement (8.5-36%). 8, 11 However, in this sample, evidence of gastrointestinal involvement was observed in 40% of the population in contrast with the 17.1 to 26% described in the literature. 8, 11 Calcinosis affects between 10 and 70% of patients with JDM. 8, 11, 12 Our study identified this disorder in 43% of the patients and it was associated with severe cases of the disease, where there was cardiac involvement and immunosuppressors had been required.
Dystrophic calcifications are calcium deposits that appear in subcutaneous tissue, muscles, fascia and tendons, with a preference for the upper and lower limbs and traumatized areas, as demonstrated by this population. 18 In this study calcinosis cutis circumscripta predominated, in agreement with the literature. 10, 20 One relevant feature was the presence of calcinosis all over the body surface, which had occurred in 1/5 of all cases. These diffuse deposits are associated with severe and long-term cases. 10, 18 As was observed here, calcinosis may precede the diagnosis of JDM, but is generally most common between the first and third years of the disease. Nevertheless, there is a report of calcinosis emerging 12 years after onset of the inflammatory myopathy. There are few descriptions of the cardiac involvement of JDM, although it is known that myocarditis, pericarditis and conductive disorders can occur. The treatment of calcinosis is itself controversial, since spontaneous involution of the condition can even occur. 10, 29 Reports exist of good efficacy and absent or rare adverse events being obtained with EDTA, diltiazem and bisphosphonates (alendronate or pamidronate), and also with surgical excision and localized infiltration of triamcinolone hexacetonide, 18, [26] [27] [28] [29] [30] [31] [32] [33] as was used with some of the patients studied here.
Another aspect worthy of interest was the mortality observed in this sample, caused by infection and systemic disease activity. Autopsy results showed that 5.5% of the JDM patients died from sepsis. One patient complained of recurrent abdominal pains and, at autopsy, there was evidence vasculitis of the mucosa, submucosa and serosa with ulceration and perforation of the gastrointestinal tract. In the literature this last symptom is described as occurring in up to 14% of patients with the disease. 34 One limitation to this study was the retrospective assessment of the medical records from a single tertiary pediatric rheumatology clinic, covering 16 consecutive years. Additionally, the extremely wide confidence intervals may reflect the small sample size, which is itself a function of the rarity of this disease.
Recently, scales to assess disease activity-the Disease Activity Score (DAS), 35 muscle strength -the Childhood Myositis Assessment Scale (CMAS) and the Manual Muscle Testing (MMT) system 36 -and supplementary assessment tests (capillaroscopy and magnetic resonance imaging) 37 have been used by pediatric rheumatologists to assess JDM. Prospective studies should be carried out to assess the association between calcinosis and disease activity as measured by these instruments.
In conclusion, calcinosis was a frequent finding with JDM and emerged during disease progression. The manifestation was associated with the more severe cases, those that also exhibited cardiac involvement and required immunosuppressant treatment.
